Puma Biotechnology Inc (PBYI.N)

PBYI.N on New York Stock Exchange

247.43USD
30 Oct 2014
Price Change (% chg)

$3.18 (+1.30%)
Prev Close
$244.25
Open
$241.69
Day's High
$247.72
Day's Low
$241.69
Volume
25,657
Avg. Vol
43,598
52-wk High
$278.50
52-wk Low
$33.76

PBYI.N

Chart for PBYI.N

About

Puma Biotechnology, Inc. is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to... (more)

Overall

Beta: --
Market Cap (Mil.): $7,452.05
Shares Outstanding (Mil.): 30.12
Dividend: --
Yield (%): --

Financials

Search Stocks

Puma Biotechnology cancer drug shows positive mid-stage results

- Puma Biotechnology Inc said its experimental lung cancer drug was safe to be administered with an already approved treatment for the disease in a mid-stage study.

29 Sep 2014

Puma Biotechnology cancer drug shows positive mid-stage results

Sept 29 - Puma Biotechnology Inc said its experimental lung cancer drug was safe to be administered with an already approved treatment for the disease in a mid-stage study.

29 Sep 2014

L'Oreal, Puma sign licence agreement for beauty products

PARIS, Sept 26 - French cosmetics giant L'Oreal said on Friday it had signed a licence agreement for beauty products with Germany's Puma that will become effective on Jan. 1.

26 Sep 2014

Puma renews sponsorship deal with Czech soccer FA

BERLIN, Sept 8 - German sportswear company Puma said it has renewed its partnership with the Czech Republic Football Association, extending a sponsorship deal that has been running since 1995.

08 Sep 2014

Competitors

Earnings vs. Estimates

Search Stocks